CellTherapies

Executive Summary

CellTherapies is a leading Australian CDMO specializing in GMP manufacturing of autologous and allogeneic cell and gene therapies, including CAR-T, TIL, MSC, and iPSC-derived products. Co-located with the Peter MacCallum Cancer Centre in Melbourne, the company leverages a purpose-built facility and digital-twin-enabled scale-up to support clinical and commercial supply. With over two decades of experience and a workforce of 200-500, CellTherapies offers end-to-end services including process development, technology transfer, cryopreservation, and logistics. Its strategic positioning in the rapidly growing cell therapy CDMO market, combined with expertise across multiple modalities, positions it as a key partner for developers seeking reliable manufacturing capacity in the Asia-Pacific region.

Upcoming Catalysts (preview)

• Q4 2026Expansion of GMP manufacturing capacity to meet rising demand80% success
• Q3 2026Major manufacturing contract win with a leading CAR-T or iPSC therapy developer60% success
• Q2 2027Regulatory certification for iPSC-derived product manufacturing (e.g., from TGA or EMA)70% success